Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03487666
Title OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Georgetown University
Indications

triple-receptor negative breast cancer

Therapies

Capecitabine + Nivolumab

Capecitabine

Nivolumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
MedStar Georgetown University Hospital Recruiting Washington District of Columbia 20007 United States Details
MedStar Washington Hospital Center Recruiting Washington District of Columbia 20010 United States Details
University of Chicago Recruiting Chicago Illinois 60637 United States Details
John Theurer Cancer Center at Hackensack University Medical Center Recruiting Hackensack New Jersey 07601 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field